Clinical trial
Optimize Neoadjuvant Therapy in HER2-Positive Early-Stage Breast Cancer
NCT07402473
Study timeline
Study start (actual)2026-03-26Date precision: day
Registry last updated2026-04-23
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
HER2-positive Early-stage Breast Cancerunresolved
Interventions
TrastuzumabDRUG · verified · RxNorm: trastuzumab
PertuzumabDRUG · verified · RxNorm: pertuzumab
DocetaxelDRUG · verified · RxNorm: docetaxel
CarboplatinDRUG · verified · RxNorm: carboplatin
Sponsors & collaborators
Rutgers, The State University of New Jerseylead sponsor
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT07402473 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.